Telix (ASX:TLX) share price jumps 7% on major Merck collaboration

Telix shares are nearing a record high on Wednesday…

| More on:
active person star jumping amid city landscape

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a very strong performer on Wednesday.

The molecularly targeted radiation (MTR) focused biopharmaceutical company's shares have jumped 7% to $6.53 today.

This means the Telix share price is now trading close to its record high of $6.65.

Why is the Telix share price storming higher?

The Telix share price is being bid higher by investors today following the release of a promising announcement this morning.

According to the release, the company has entered into a pan-cancer clinical collaboration with pharmaceutical giant Merck. This builds on the success of a strategic research collaboration agreement between the two companies in 2019.

The release explains that the agreement will see the two parties conduct combination studies with one of Merck's investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix's TLX591 and TLX250 MTR therapeutic programs.

TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. The collaboration will investigate the synergy of these investigational assets with Merck's DDRi compound across a wide variety of oncology indications.

"The vanguard of nuclear medicine and oncology"

Telix's CEO, Dr. Christian Behrenbruch, appeared to be very pleased with the agreement.

He said: "This collaboration represents the vanguard of nuclear medicine and oncology, and we are excited by the level of new data and intellectual property already generated, which is highly supportive of clinical translation."

"Pre-clinical studies provide evidence that the combined effect of Merck's DDRi compound with Telix's MTR candidates has potential to significantly impact cancer by improving efficacy and reducing the required radiation dose for tumour reduction and remission, compared to MTR only," Dr Behrenbruch added.

Today's gain means the Telix share price is smashing the market in 2021 and now up over 60% year to date.

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »